For Lactose Intolerance
6-Strain Probiotic + Lactase
Probiotics are beneficial bacteria essential for improving intestinal health.
ProbiLIFT L is a probiotic supplement specifically formulated with 6 probiotic strains and lactase.
Why 6 strains?
The beneficial effects of probiotics are both strain-and dose-specific. A combination of various probiotic strains working together has been shown to be the most effective in the gut1. In addition, more significant results can be achieved with multiple strains in combination compared to single strain preparations2.
Scheduling status: S0. Proprietary name (and dosage form): PROBILIFT L (capsules). Pharmacological classification: D.34.9 Probiotic. Complementary Medicine. Health Supplement. Pharmacological action: Probiotics are beneficial bacteria, essential for improving intestinal health. PROBILIFT L is a probiotic supplement specially formulated with 6 probiotic strains and lactase. Probiotics can increase the levels of beneficial bacteria in the gut, creating an environment that is unfavourable to the growth of harmful bacteria. By introducing live probiotic cultures, like what is contained in PROBILIFT L to the intestinal tract, the beneficial gut flora populations are increased and transitory flora, including pathogenic or bad bacteria, are not able to colonise the intestine. PROBILIFT L contains the enzyme lactase, a naturally occurring enzyme that helps the body to break down the complex sugar lactose, found in milk, breastmilk, some infant formulas and dairy products. Infants may have difficulty digesting lactose, resulting in trapped wind and flatulence, vomiting, diarrhoea, and long periods of restlessness and crying. PROBILIFT L helps the body to digest lactose and manage symptoms of lactose intolerance. PROBILIFT L has been specially formulated to assist with the symptoms of lactose intolerance. Probiotics should normalise the microbial balance in the human intestines when ingested on a regular basis thereby supporting the functioning of the digestive tract. Identification: PROBILIFT L contains a cream coloured liquid with white suspended particles. Presentation PROBILIFT L is packed in a 30 ml amber glass bottle containing 30 ml of liquid, with a black plastic tamper evident cap and a graduated glass pipette. Each carton contains 1 blister strip. Agera Health. firstname.lastname@example.org. www.agerahealth.co.za. 30 ml.
- Timmerman, H. M., Koning, C. J., Mulder, L., Rombouts, F. M., Beynen, A. C. (2004). Monostrain, multistrain and multispecies probiotics: a comparison of functionality and efficacy. International Journal of Food Microbiology, 96(3), 219-233.
- Leyer, G. J., Li, S., Mubasher, M. E., Reifer, C., Arthur C. Ouwehand, A. C. (2009). Probiotic Effects on Cold and Influenza-Like Symptom Incidence and Duration in Children. Pediatrics, 124, 172-179.
- Kyne, L., Kelly, C. P. (2001). Recurrent Clostridium difficile diarrhoea. Gut, 49, 152–153.
- Ringel, Y., Ringel-Kulka, T., Maier, D., Carroll, I., Galanko, J. A., Leyer, G., Palsson, O. S. (2011). Clinical trial: Probiotic Bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 Versus Placebo for the Symptoms of Bloating in Patients with Functional Bowel Disorders – a Double-Blind Study. Journal of Clinical Gastroenterology, 45(6), 518–525.
- Van der Kleij, H., O’Mahony, C., Shanahan, F., O’Mahony, L., Bienenstock, J. (2008). Protective effects of Lactobacillus reuteri and Bifidobacterium infantis in murine models for colitis do not involve the vagus nerve. American Journal of Physiology- Regulatory, Integrative & Comparative Physiology, 295, 1131–1137.
- Biagi, E., Candela, M., Fairweather-Tait, S., (2012). Aging of the human metaorganism: the microbial counterpart. Age, 34, 247–267.
- Sazawal, S., Hiremath, G., Dhingra, U., Malik, P., Deb, S, Black, R. E. (2006). Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomised, placebo-controlled trials. The Lancet Infectious Diseases, 6(6), 374 –382.
- Guandalini, S. (2006). Probiotics for children: use in diarrhea. Journal of Clinical Gastroenterology, 40(3), 244–248.
- Rautava, S., Kalliomaki, M., Isolauri, E. (2005). New therapeutic strategy for combating the increasing burden of allergic disease: probiotics: a Nutrition, Allergy, Mucosal Immunology and Intestinal Microbiota (NAMI) Research Group report. Journal of Allergy & Clinical Immunology, 116(1, 31–37.
- Fooks, L. J., Fuller, R., Gibson, G. R. (1999). Prebiotics, probiotics and human gut microbiology. International Dairy Journal, 9, 53-61.
- Binns, N. (2013.) Probiotics, Prebiotics and the Gut Microbiota. ILSI Europe Concise Monograph Series.